Richell Booijink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richell Booijink has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ruchi Bansal
Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands
19 shared publications - Brigitte C. M. Haberkorn
Department of Medical Oncology, Maasstad Hospital , Rotterdam, 3079 DZ
18 shared publications - Danny Houtsma
Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands
18 shared publications - Eshwari Dathathri
Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, 7522 NB Enschede, The Netherlands
18 shared publications - Fikri Abali
Department of Medical Cell Biophysics, Technical Medical Center, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands
18 shared publications - Jaco Kraan
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
18 shared publications
Latest Publications
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Distribution of CTC groups in the nanowells. A, Percentage of PSA-secreting and non-secreting cells detected in the nanowells and analyzed using the SPOT software. B, Percentage of PSMA+ and PSMA− cells identified in the nanowells. There were 0 CTC captured in the nanowells of the first three DLA. The total CTC counts in the nanowells are represented for each patient above the columns.
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Distribution of CTC groups in the nanowells. A, Percentage of PSA-secreting and non-secreting cells detected in the nanowells and analyzed using the SPOT software. B, Percentage of PSMA+ and PSMA− cells identified in the nanowells. There were 0 CTC captured in the nanowells of the first three DLA. The total CTC counts in the nanowells are represented for each patient above the columns.
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
PSA protein calibration curve (A): Serial dilutions of PSA protein spotted on PVDF membrane, stained and visualized in FITC. (B): Calibration graph of PSA (pg/μm2) versus the normalized mean intensity of the spots (R2 = 0.97).
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
PSA protein calibration curve (A): Serial dilutions of PSA protein spotted on PVDF membrane, stained and visualized in FITC. (B): Calibration graph of PSA (pg/μm2) versus the normalized mean intensity of the spots (R2 = 0.97).
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
CTC recovery after sorting and seeding on nanowells
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
CTC recovery after sorting and seeding on nanowells
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Steps used to determine the area of the PSA spots produced by single CTC. Images of the membranes with the PSA products from single CTC cells were segmented in Image J software (version 1.54g). Once the spots were segmented, the minimum and maximum pixel area size was set to exclude artefacts. As the PSA spots were round in shape, a roundness values between 0.64 and 1.0 was used to exclude unwanted objects. (A) depicts the a part of a PVDF membrane with the PSA spots from CTC. (B) Illustrates the segmented image and the area-id. (C) shows a mask generated with Image J used to check which spots were measured. (D) Once the areas of the PSA spots were determined the spot software was used to link the PSA spots, the area of the spots extracted with image J with the corresponding CTC (well-id). In practice, once the correct threshold value and particle size range was determined, the particle analysis plugin in image J was then used to determine the area of each segmented spot. Next, to corelate the spot area and the well-number (the cell that secreted the PSA), the PSA membrane (A), and the segmented membrane (B) were loaded and aligned in the VyCAP spot software. The VyCAP software segments the image to extract the spot Intensity and well-id (PSA membrane (A) and this is correlated with the spot area-id image created in image J. The blue and red box (first row) in panel D, show the well-id and the spot intensity.
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Steps used to determine the area of the PSA spots produced by single CTC. Images of the membranes with the PSA products from single CTC cells were segmented in Image J software (version 1.54g). Once the spots were segmented, the minimum and maximum pixel area size was set to exclude artefacts. As the PSA spots were round in shape, a roundness values between 0.64 and 1.0 was used to exclude unwanted objects. (A) depicts the a part of a PVDF membrane with the PSA spots from CTC. (B) Illustrates the segmented image and the area-id. (C) shows a mask generated with Image J used to check which spots were measured. (D) Once the areas of the PSA spots were determined the spot software was used to link the PSA spots, the area of the spots extracted with image J with the corresponding CTC (well-id). In practice, once the correct threshold value and particle size range was determined, the particle analysis plugin in image J was then used to determine the area of each segmented spot. Next, to corelate the spot area and the well-number (the cell that secreted the PSA), the PSA membrane (A), and the segmented membrane (B) were loaded and aligned in the VyCAP spot software. The VyCAP software segments the image to extract the spot Intensity and well-id (PSA membrane (A) and this is correlated with the spot area-id image created in image J. The blue and red box (first row) in panel D, show the well-id and the spot intensity.
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Table 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Table 1 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Workflow schematically illustrating the DLA processing to obtain viable CTCs. (1) DLA enrichment using the reduced enrichment reagent (RER) protocol; (2) staining using anti–PSMA-PE, anti–CD45-APC, and viability dye calcein AM; (3) sorting of calcein+ and CD45– CTCs enriched from the DLA; (4) seeding into the VyCAP nanowells; (5) imaging using a fluorescence inverted scanning microscope to visualize cells captured in the nanowells; (6) PSA secretion from single cells and PSA capture overnight (24 hours) using an anti–PSA-coated membrane and addition of anti–IgG-PE to visualize the imprint; (7) staining of the membrane for visualization of PSA secretion spots; and (8) correlation of PSA spots with cells with the help of imprint and the SPOT software to identify PSA-secreting and non-secreting PSMA+/PSMA− CTCs.
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Workflow schematically illustrating the DLA processing to obtain viable CTCs. (1) DLA enrichment using the reduced enrichment reagent (RER) protocol; (2) staining using anti–PSMA-PE, anti–CD45-APC, and viability dye calcein AM; (3) sorting of calcein+ and CD45– CTCs enriched from the DLA; (4) seeding into the VyCAP nanowells; (5) imaging using a fluorescence inverted scanning microscope to visualize cells captured in the nanowells; (6) PSA secretion from single cells and PSA capture overnight (24 hours) using an anti–PSA-coated membrane and addition of anti–IgG-PE to visualize the imprint; (7) staining of the membrane for visualization of PSA secretion spots; and (8) correlation of PSA spots with cells with the help of imprint and the SPOT software to identify PSA-secreting and non-secreting PSMA+/PSMA− CTCs.
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Correlation of PSA CTC vs PSA serum in the processed blood volume of 9 mCNPC patients in whom PSA-secreting CTC were identified. A weak positive correlation was observed with Spearman coefficient (ρ) = 0.28.
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Correlation of PSA CTC vs PSA serum in the processed blood volume of 9 mCNPC patients in whom PSA-secreting CTC were identified. A weak positive correlation was observed with Spearman coefficient (ρ) = 0.28.
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
PSA secretions (pg/cell) from single CTC and total CTC captured in nanowell array from patients with mCNPC (n = 18). A, The PSMA+ PSA+ (in red) and PSMA−PSA+ (in yellow) indicate the two subpopulations of CTC that secrete. The PSMA+ PSA− (in green) and PSMA−PSA− (in blue) indicate the two subpopulations of CTC that are non-secreting cells. The serum PSA (ng/mL) and the CTC in 7.5 mL of blood are indicated on the secondary x-axis. B, Total counts of the CTC captured in the nanowell array indicating PSMA+ PSA+ (in red), PSMA−PSA+ (in yellow), PSMA+ PSA− (in green), and PSMA−PSA− (in blue).
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
PSA secretions (pg/cell) from single CTC and total CTC captured in nanowell array from patients with mCNPC (n = 18). A, The PSMA+ PSA+ (in red) and PSMA−PSA+ (in yellow) indicate the two subpopulations of CTC that secrete. The PSMA+ PSA− (in green) and PSMA−PSA− (in blue) indicate the two subpopulations of CTC that are non-secreting cells. The serum PSA (ng/mL) and the CTC in 7.5 mL of blood are indicated on the secondary x-axis. B, Total counts of the CTC captured in the nanowell array indicating PSMA+ PSA+ (in red), PSMA−PSA+ (in yellow), PSMA+ PSA− (in green), and PSMA−PSA− (in blue).
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
DLA samples isolated in nanowells (A): Example of a non-sorted DLA sample showing the presence of cell debris with non-specific staining in PE, FITC and APC channels, making it difficult to identify intact live CTC. (B): Example of sorted DLA sample with the absence of cell debris and a clear indication of live CTC in the nanowells.
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
DLA samples isolated in nanowells (A): Example of a non-sorted DLA sample showing the presence of cell debris with non-specific staining in PE, FITC and APC channels, making it difficult to identify intact live CTC. (B): Example of sorted DLA sample with the absence of cell debris and a clear indication of live CTC in the nanowells.
- Open Access
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Flow cytometry analysis of EpCAM-enriched DLA sample. A, Flow plot showing the forward and side scatter of the sample with a gate excluding small events (in black). B, CD45-APC vs. calcein AM scatter plot of the events with a gate on the calcein+ CD45− cells (in green) with all other events (in red).
- 18 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients
Flow cytometry analysis of EpCAM-enriched DLA sample. A, Flow plot showing the forward and side scatter of the sample with a gate excluding small events (in black). B, CD45-APC vs. calcein AM scatter plot of the events with a gate on the calcein+ CD45− cells (in green) with all other events (in red).